Neon Therapeutics, Inc. (NasdaqGS: NTGN) will look for acquisitions. Neon Therapeutics has filed for shelf registration in which Neon Therapeutics may from time to time sell any combination of the securities described in the prospectus in one or more offerings for an aggregate initial offering price of up to $200,000,000. Neon Therapeutics intends to use the net proceeds from the sale of any securities offered under the prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include research and development costs, including the conduct of one or more clinical trials and process development and manufacturing of our product candidates, potential strategic acquisitions of complementary businesses or assets, services or technologies, expansion of our technology or manufacturing infrastructure and capabilities, working capital, capital expenditures and other general corporate purposes.